Skip to content

Advertisement

  • Research note
  • Open Access

Polymorphism rs13334190 in zinc finger protein 469 (ZNF469) is not a risk factor for keratoconus in a Saudi cohort

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 1,
  • 4 and
  • 1, 5, 6Email author
BMC Research Notes201710:652

https://doi.org/10.1186/s13104-017-2996-8

  • Received: 19 July 2017
  • Accepted: 25 November 2017
  • Published:

Abstract

Objective

Polymorphism rs13334190 in the zinc finger protein 469 gene has been suggested to predispose toward a “thin” cornea, which then becomes keratoconic or is directly pathogenic. Thus, we genotyped polymorphism rs13334190 in 127 unrelated keratoconus cases and 168 control subjects from Saudi Arabia using Taq-Man® assay.

Results

The genotype frequency distribution did not deviate significantly from the Hardy–Weinberg equilibrium (p > 0.05). Overall, both the genotype and allele frequencies were not significantly different between cases and controls. A minor allele frequency of 0.068 was comparable to the aggregate rates ranging from 0.060 to 0.086 observed in other populations. Binary logistic regression analysis was performed to ascertain the effects of age, gender and genotype on the likelihood of having keratoconus. The analysis indicated that increased age was statistically significant (p = 0.000) and that females have a 2.19-fold increased risk (p = 0.018) of developing keratoconus. The genotype frequencies did not differ between the sporadic or familial keratoconus cases. Polymorphism rs13334190 is not an independent risk factor for keratoconus in the Saudi cohort.

Keywords

  • Saudi
  • Keratoconus
  • rs13334190
  • ZNF469

Introduction

Keratoconus (KTCN; OMIM 148300) is a non-inflammatory corneal ectatic disease resulting in steepening and distortion of the cornea, altered refractive powers and altered visual acuity. Advanced cases of KTCN exhibit corneal scarring due to corneal edema and decompensation that may further reduce the visual acuity. The clinical symptoms of KTCN are highly variable and depend upon the stage of progression of the disease [1]. The prevalence of KTCN has been reported to vary among different studies, ranging from 0.3 per 100,000 in Russia to 2300 per 100,000 in central India [2] and this variation is in part due to the differences in the applied diagnostic criteria and geographic location. The disease occurs with no ethnic or gender preponderance and causes significant visual impairment [2].

Increased evidence suggests an involvement of a genetic component in disease susceptibility. This hypothesis is getting widely accepted, especially with the predominance of KTCN among certain families, twins and particular ethnicities [3]. Accordingly, family history is an important risk factor and obtaining a thorough family medical history is crucial when considering a refractive surgery. Various candidate single nucleotide polymorphisms (SNPs), genes and copy number variations have been associated with the susceptibility to KTCN [4]. In addition, mitochondrial abnormalities have also been reported [5]. Reactive oxygen species are a known contributor to tissue damage and can be a significant player in the characteristic corneal thinning and ectasia that lead to the development and progression of KTCN [6]. KTCN cases exhibiting both autosomal recessive and dominant patterns of inheritance have been documented [3]. There are several chromosomal loci and genes reported in association with KTCN [7, 8], some of which were eventually excluded [7, 9], while others showed no confirmed association with the disease [10, 11]. The major genetic contributor to KTCN, however, is yet to be discovered.

In 2014, Vincent et al. [12] screened 43 Polynesian KTCN patients for mutations in the zinc finger protein 469 (ZNF469) gene. They detected three heterozygous variants, which were predicted to be pathogenic and suggested that these variants are either genetically predisposed toward a “thin” cornea, which then becomes keratoconic or are directly pathogenic. One of those variants is the p.R2129K, which is the subject of our investigation [12]. Lechner and colleagues [13] found a significant enrichment of potentially pathologic heterozygous alleles in ZNF469 associated with the development of KTCN (p = 0.00102) resulting in a relative risk of 12.0. This enrichment of the potentially pathogenic alleles in ZNF469 in 12.5% of KTCN patients represents significant mutational load and highlights ZNF469 as the most significant genetic factor responsible for KTCN identified to date. In contrast, Karolak et al. [14] found that the high prevalence of ZNF469 variants identified in Polish KTCN patient is typical for a common genetic variation observed in the general population. Therefore, authors concluded that variations in the ZNF469 gene are not responsible for KTCN in their population. Here, we tested whether SNP rs13334190 (p.R2129K) variation in the ZNF469 gene is associated with KTCN in patients from Saudi Arabia.

Main text

Methods

The study adhered to the tenets of the Declaration of Helsinki and was approved by the College of Medicine (King Saud University, Riyadh, Saudi Arabia) institutional review board committee (proposal number #09–659). Written informed consent was obtained from all participants. KTCN patients (n = 127) were selected from the anterior segment clinic at King Abdulaziz University Hospital, Riyadh, Saudi Arabia. Diagnosis of KTCN was confirmed if the Schimpff-flow based elevation map showed posterior corneal elevation with the central 5 mm ≥ + 20 µm, inferior–superior dioptric asymmetry (I–S value) > 1.2 diopters (D) and the steepest keratometry > 47 D. Identification of an isolated sporadic case or familial KTCN was done after examining the immediate family members. Individuals showing presence of post-laser-assisted in situ keratomileusis ectasia and secondary causes of KTCN such as trauma, surgery, Ehlers Danlos syndrome, osteogenesis imperfecta and pellucid marginal degeneration were excluded. Control subjects (n = 168) had no ocular disease(s) or previous ophthalmic surgeries on clinical examination. They had normal slit lamp cornea and Schimpff-flow based elevation map. Subjects refusing to participate in this study were excluded.

DNA preparation

DNA was extracted from EDTA blood samples using the illustra blood genomicPrep Mini Spin kit (Catalog No. 28904265, GE Healthcare, Buckinghamshire, UK) and stored at – 20 °C in aliquots until further use.

Genotyping of rs13334190 in ZNF469

DNA samples were genotyped for polymorphism rs13334190 using the TaqMan® SNP genotyping assay (Applied Biosystems Inc., Foster City, CA, USA) on ABI 7500 real-time PCR system (applied biosystems) as described previously [15]. For genotyping rs13334190 polymorphism, assay ID: C_30944445_10 (applied biosystems) was used. A 25 µL PCR reaction consisted of 1X TaqMan® genotyping master mix (applied biosystems), 1X SNP genotyping assay mix and 20 ng DNA. Each 96-well plate included two no DNA negative controls. The recommended PCR conditions included incubation at 95 °C for 10 min, followed by 40 cycles, denaturation at 92 °C for 15 s and annealing/extension at 60 °C for 1 min. The VIC® and 6-carboxy-fluorescein (FAM) fluorescence levels of the PCR products were measured at 60 °C for 1 min. Genotype calling was performed using the automated 2-color allele discrimination software on ABI 7500.

Statistical analysis

Independent sample’s t test (2-tailed) was used to test difference between cases and controls in terms of continuous variables. Pearson’s Chi2 test was used to test Hardy–Weinberg equilibrium (HWE) deviation and detect any association between the different genetic profiles. Risk was expressed as odds ratio (OR) with 95% confidence interval (CI) level. A p value less than 0.05 were considered statistically significant. All the analysis was done using SPSS version 22 (IBM Inc. Chicago, Illinois, USA).

Results

The demographic and other characteristics of subjects included in this study are shown in Table 1. A total number of 295 subjects, including, 127 cases of KTCN and 168 controls were genotyped in this study. KTCN cases included both isolated, sporadic cases (n = 85) and familial cases (n = 42). The results presented in Table 1, indicate that the patient group was significantly younger than the control group with age ranging from 12 to 50 year and 20 to 90 year, respectively. In addition, the gender distribution between the two study group was also found to be significantly different (p = 0.010).
Table 1

Demographic characteristics in keratoconus patients and controls

Demographic characteristics

Patients (n = 127)

No. (%)

Controls (n = 168)

No. (%)

p value (2-tailed)

Age in years, mean (± SD)

26.9 (6.6)

46.9 (15.2)

0.000*

Male

65 (51.1)

111 (66.0)

0.010§

Female

62 (48.8)

57 (33.9)

Familial keratoconus

42 (33)

t test, § Pearson Chi2 test

The distribution of rs13334190 polymorphism did not deviate significantly from the HWE (p > 0.05). Association analysis between cases and controls revealed no significant genotype distribution under additive (Chi2 = 1.90, df = 2, p = 0.387) and dominant models (Chi2 = 1.43, df = 1, p = 0.232). Besides, the allele frequency distribution was also non-significant (OR = 0.616; 95% CI = 0.29–1.28; p = 0.194). The minor “A” allele frequency was 0.043 and 0.068 among KTCN patients and controls, respectively (Table 2). In addition, to ascertain the effects of age, gender and genotype on the likelihood of having KTCN a binary logistic regression analysis was performed. The analysis indicated that increased age was statistically significant (p = 0.000) and that females were having a 2.19-fold increased risk (p = 0.018) of developing KTCN (Table 3). Furthermore, the distributions between sporadic (n = 85) and familial cases (n = 42) were similar. The homozygous genotype was absent, whereas, the heterozygous genotype G/A was 9.5 and 9.4% in familial and sporadic KTCN cases, respectively.
Table 2

Association analysis of rs13334190 in ZNF469 gene with keratoconus

SNP (gene)

rs13334190 (ZNF469)

Allelic analysis

Patients

(n = 127)

No. (%)

Controls

(n = 168)

No. (%)

Odds ratio

95% confidence interval

p valuea (2-tailed)

G

243 (0.956)

313 (0.931)

1

Reference

Ab

11 (0.043)

23 (0.068)

0.616

0.294–1.288

0.194

HWE p

0.61

0.79

Genotype and model analysis

 G/G

116 (91.3)

146 (86.9)

1

Reference

 G/A

11 (8.6)

21 (12.5)

0.659

0.30–1.42

0.285

 A/A

0 (0)

1 (0.6)

 Additive (trend)

0.387

 Dominant

0.629

0.29–1.35

0.232

aPearson Chi2 test

bRisk variant, HWE p Hardy–Weinberg equilibrium p value

Table 3

Effect of age, sex and genotype on disease outcome by binary logistic regression analysis

Variables

Odds ratio

95% confidence interval

p value (2-tailed)

Age

0.83

0.80–0.87

0.000

Sexa

2.19

1.14–4.18

0.018

Dominant modelb

0.76

0.27–2.16

0.612

aMale as reference

bG/G as reference

Discussion

The SNP rs13334190 in the ZNF469 was previously reported in association with thin cornea and KTCN. Here, we screened a group of KTCN patients and controls from the Saudi Arab ethnicity. The heterozygous and homozygous mutant genotype distribution was similar and did not yield significant statistical difference. Similarly, the minor allele frequency was similar in the two study groups, indicating that the allele and mutant genotypes are not an independent risk factor for KTCN in this population. This finding is similar to previous studies, which could not establish a link between rs13334190 and KTCN in the Polish population [14]. In the same report, Karolak and colleagues [14] reported that this SNP is a benign polymorphism diminishing its pathogenic significance. In contrast, the rs13334190 SNP was predicted to be pathogenic in a cohort of New Zealand despite the lack of clear explanation of its role in KTCN-pathogenicity and its Polynesian controls at a rate > 1% [12]. Lechner and colleagues [13] found a significant association between this SNP and KTCN in a European cohort from the UK and Switzerland.

In our KTCN cohort of Saudi origin (n = 127), 42 (33.1%) were familial cases, whereas 85 (66.9%) were sporadic. The prevalence of high percentage of familial KTCN cases is unusual and may be reflected by the high consanguineous marriages in Saudi Arabia as we reported previously [16]. When we investigated the genetic difference for SNP rs13334190 in familial and sporadic cases, we did not find any difference. Higher familial cases in our population may indicate an autosomal recessive gene(s) yet to be detected.

The minor ‘A’ allele frequency found in Saudi controls is 0.068, which is comparable to rates observed in various populations, which ranged from 0.060 to 0.086 (http://www.ensembl.org). In contrast, the minor allele frequency in Polynesian population was 0.14 and this clearly reflects an ethnicity-based variation. A higher rate of the minor allele in the Polynesians as compared to others may be reflected by the fact that Polynesian is an Islander population and may be regarded as genetically isolated population.

The study provides no evidence of any association between SNP rs13334190 in ZNF469 gene and KTCN patients of Saudi origin.

Limitations

The number of patients with KTCN and controls in this study was relatively small as was the sample size in each subgroup. Therefore, the lack of significance in our study could be due to relatively small sample size and insufficient statistical power of this study cohort. Population-based replication studies in different ethnic groups are necessary to identify and/or confirm genetic contribution of rs13334190 or other SNP(s) in ZNF469 to KTCN.

Abbreviations

CI: 

confidence interval

HWE: 

Hardy–Weinberg equilibrium

KTCN: 

keratoconus

OR: 

odds ratio

SNP: 

single nucleotide polymorphism

ZNF469

zinc finger protein 469

Declarations

Authors’ contributions

HK: study design, subject recruitment, clinical examination, clinical data, manuscript draft preparation; AAK: data interpretation, statistical analysis, critical revision of manuscript; TS: performed genotyping experiments, results, data collection; TAA: sample collection and DNA extraction, results, data collection; NAA, MAA, AAM: subject recruitment, clinical examination, clinical data; performed experiments; YL: study design, critical revision of manuscript; KAA: study design, overall supervision, and preparation of final version of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank the Deanship of Scientific Research, Glaucoma Research Chair at the King Saud University for allowing to use the laboratory facilities.

Competing interests

The authors declare that they have no competing interests and the work was not supported or funded by any drug company. The paper has not been presented in any previous conference or scientific meeting.

Availability of data

The data supporting the conclusions of this article are all presented within the article.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study adhered to the tenets of the Declaration of Helsinki and had received approval from the Institutional Review Board and Research Ethics Committee of College of Medicine, King Saud University, Riyadh, Saudi Arabia. Written, informed consent was obtained from all participants prior to their inclusion in this study.

Funding

This work was supported by King Saud University, Deanship of Scientific Research, Glaucoma Research Chair but had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Glaucoma Research Chair, Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, 11411, Saudi Arabia
(2)
Ophthalmology Department, College of Medicine, King Khalid University, P.O. Box 641, Abha, 61421, Saudi Arabia
(3)
Assir Central Hospital, P. O. Box 35, Abha, 61421, Saudi Arabia
(4)
Augusta University, 1460 Laney Walker Blvd, CB1123, Augusta, GA 30912, USA
(5)
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA
(6)
Ophthalmic Genetics Laboratory, Department of Ophthalmology, College of Medicine, King Saud University, P.O. Box 245, Riyadh, 11411, Saudi Arabia

References

  1. Espandar L, Meyer J. Keratoconus: overview and update on treatment. Middle East Afr J Ophthalmol. 2010;17(1):15–20.PubMedPubMed CentralGoogle Scholar
  2. Gokhale NS. Epidemiology of keratoconus. Indian J Ophthalmol. 2013;61(8):382–3.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Abu-Amero KK, Al-Muammar AM, Kondkar AA. Genetics of keratoconus: where do we stand? J Ophthalmol. 2014;2014:641708.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Abu-Amero KK, Kondkar AA, Azad TA, Sultan T, Kalantan H, Al-Muammar AM. Keratoconus is associated with increased copy number of mitochondrial DNA. Mol Vis. 2014;20:1203–8.PubMedPubMed CentralGoogle Scholar
  5. Abu-Amero KK, Azad TA, Kalantan H, Sultan T, Al-Muammar AM. Mitochondrial sequence changes in keratoconus patients. Invest Ophthalmol Vis Sci. 2014;55(3):1706–10.View ArticlePubMedGoogle Scholar
  6. Wojcik KA, Kaminska A, Blasiak J, Szaflik J, Szaflik JP. Oxidative stress in the pathogenesis of keratoconus and Fuchs endothelial corneal dystrophy. Int J Mol Sci. 2013;14(9):19294–308.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Rabinowitz YS. The genetics of keratoconus. Ophthalmolo Clin N Am. 2003;16(4):607–20.View ArticleGoogle Scholar
  8. Bisceglia L, De Bonis P, Pizzicoli C, Fischetti L, Laborante A, Di Perna M, Giuliani F, Delle Noci N, Buzzonetti L, Zelante L. Linkage analysis in keratoconus: replication of locus 5q21.2 and identification of other suggestive Loci. Invest Ophthalmol Vis Sci. 2009;50(3):1081–6.View ArticlePubMedGoogle Scholar
  9. Fullerton J, Paprocki P, Foote S, Mackey DA, Williamson R, Forrest S. Identity-by-descent approach to gene localisation in eight individuals affected by keratoconus from north-west Tasmania, Australia. Hum Genet. 2002;110(5):462–70.View ArticlePubMedGoogle Scholar
  10. Eran P, Almogit A, David Z, Wolf HR, Hana G, Yaniv B, Elon P, Isaac A. The D144E substitution in the VSX1 gene: a non-pathogenic variant or a disease causing mutation? Ophthalmic Genet. 2008;29(2):53–9.View ArticlePubMedGoogle Scholar
  11. Tang YG, Picornell Y, Su X, Li X, Yang H, Rabinowitz YS. Three VSX1 gene mutations, L159M, R166W, and H244R, are not associated with keratoconus. Cornea. 2008;27(2):189–92.View ArticlePubMedGoogle Scholar
  12. Vincent AL, Jordan CA, Cadzow MJ, Merriman TR, McGhee CN. Mutations in the zinc finger protein gene, ZNF469, contribute to the pathogenesis of keratoconus. Invest Ophthalmol Vis Sci. 2014;55(9):5629–35.View ArticlePubMedGoogle Scholar
  13. Lechner J, Porter LF, Rice A, Vitart V, Armstrong DJ, Schorderet DF, Munier FL, Wright AF, Inglehearn CF, Black GC, et al. Enrichment of pathogenic alleles in the brittle cornea gene, ZNF469, in keratoconus. Hum Mol Genet. 2014;23(20):5527–35.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Karolak JA, Gambin T, Rydzanicz M, Szaflik JP, Polakowski P, Frajdenberg A, Mrugacz M, Podfigurna-Musielak M, Stankiewicz P, Gajecka M. Evidence against ZNF469 being causative for keratoconus in Polish patients. Acta Ophthalmol. 2016;94(3):289–94.View ArticlePubMedGoogle Scholar
  15. Abu-Amero KK, Kondkar AA, Mousa A, Osman EA, Al-Obeidan SA. Association of Mn-SOD mutation (c.47T > C) with various POAG clinical indices. Ophthalmic Genet. 2014;35(2):85–90.View ArticlePubMedGoogle Scholar
  16. Abu-Amero KK, Kalantan H, Al-Muammar AM. Analysis of the VSX1 gene in keratoconus patients from Saudi Arabia. Mol Vis. 2011;17:667–72.PubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement